stockportfolio.pro
Stocks / ILMN vs WST
ILMN vs WST
Illumina, Inc. and West Pharmaceutical Services, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Illumina, Inc. (ILMN) | West Pharmaceutical Services, Inc. (WST) | |
|---|---|---|
| Market cap | $24.7B | $23.6B |
| Revenue (latest FY) | $4.34B | $3.07B |
| Net income (latest FY) | $850.00M | $493.70M |
| Revenue growth (5y CAGR) | 6.0% | 7.4% |
| Net margin | 19.6% | 16.1% |
| Return on equity | 31.2% | 15.5% |
| P/E ratio | 29.6 | 44.7 |
| Dividend yield | — | 0.3% |
| Profitable years (of last 10) | 7 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ILMN — free Open WST — freeFrequently asked questions
Which is bigger, ILMN or WST?
Illumina, Inc. is larger by market capitalization — $24.7B versus $23.6B.
Which grows faster, ILMN or WST?
Over the last five fiscal years, West Pharmaceutical Services, Inc. grew revenue faster — 7.4%/yr versus 6.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.